Rebiotix Inc., a Roseville, MN-based biotechnology company, raised $25m in Series B Funding.
The company, which has now raised $30m since inception, intends to use the funds to support pivotal clinical research to advance lead product RBX2660 (microbiota suspension) towards commercialization; for research and development on therapeutic products, new treatment indications, and general working capital.
Led by Lee Jones, Founder, President and CEO, Rebiotix is a biotechnology company focused on pioneering Microbiota Restoration Therapy to restore healthy gut flora through the transplantation of live microorganisms. The company is developing an entirely new category of biologic drugs designed to reverse pathogenic processes responsible for disease through the transplantation of live human-derived microbes. RBX2660 is a non-antibiotic treatment under study for recurrent Clostridium difficile (C. diff.) infection.
Rebiotix is currently working with the FDA to finalize plans for additional clinical studies needed to achieve regulatory approval for RBX2660.